Molecular assays may aid bladder cancer control

Washington-An evolution in the management of bladder cancer, including the use of molecular-based diagnostic testing, may soon make it possible to achieve better outcomes at a lower cost, according to Mark P. Schoenberg, MD. Dr. Schoenberg, associate professor of urology and oncology and director of the bladder cancer research center at the Johns Hopkins School of Medicine in Baltimore, said that a change in some aspects of bladder cancer management is sorely needed.

Related Videos

Related Content

Advertisement

February 21st 2025

Piflufolastat F 18 yields high detection rate even at low PSA levels for prostate cancer

Benjamin P. Saylor

Total detection rate was 36% (13/36) in the ultra-low PSA group and 51% (47/93) in the low-PSA group.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 20th 2025

Final CheckMate 9ER data show long-term efficacy of nivolumab/cabozantinib in RCC

Benjamin P. Saylor

Robert J. Motzer, MD, reported that median PFS was 16.4 months in the nivolumab plus cabozantinib arm (95% CI, 12.5-19.3) vs 8.3 months in the sunitinib arm (95% CI, 7.0-9.7) (HR=0.58, 95% CI, 0.49-0.70).

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 20th 2025

CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC

Thomas E. Hutson, DO, PharmD

"The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.

February 19th 2025

Level of service for vasectomy prompts coding confusion

Jonathan Rubenstein, MD Mark Painter

"With the requirements for an E/M code as noted above, we agree with you that the supporting documentation, if appropriately documented, would support a level 3 outpatient visit for a visit regarding counseling for contraception or family planning," write Jonathan Rubenstein, MD, and Mark Painter.

Related Content

Advertisement

February 21st 2025

Piflufolastat F 18 yields high detection rate even at low PSA levels for prostate cancer

Benjamin P. Saylor

Total detection rate was 36% (13/36) in the ultra-low PSA group and 51% (47/93) in the low-PSA group.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 20th 2025

Final CheckMate 9ER data show long-term efficacy of nivolumab/cabozantinib in RCC

Benjamin P. Saylor

Robert J. Motzer, MD, reported that median PFS was 16.4 months in the nivolumab plus cabozantinib arm (95% CI, 12.5-19.3) vs 8.3 months in the sunitinib arm (95% CI, 7.0-9.7) (HR=0.58, 95% CI, 0.49-0.70).

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 20th 2025

CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC

Thomas E. Hutson, DO, PharmD

"The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.

February 19th 2025

Level of service for vasectomy prompts coding confusion

Jonathan Rubenstein, MD Mark Painter

"With the requirements for an E/M code as noted above, we agree with you that the supporting documentation, if appropriately documented, would support a level 3 outpatient visit for a visit regarding counseling for contraception or family planning," write Jonathan Rubenstein, MD, and Mark Painter.